M. K. Pasha

发表

Microsoft Word-70929949-file00.docx

Changyong Hu, P. Yeo, K. Ethirajulu, 2011 .

Pharmacodynamic Evaluation of the Target Efficacy of SB939, an Oral HDAC Inhibitor with Selectivity for Tumor Tissue

J. Wood, B. Goh, W. Yong, 2011, Molecular Cancer Therapeutics.

In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species.

K. Sangthongpitag, P. Yeo, E. Kantharaj, 2007, Biological & pharmaceutical bulletin.

2-anilino-4-aryl-8H-purine derivatives as inhibitors of PDK1.

Chang Kai Soh, Kay Lin Goh, Z. Bonday, 2012, Bioorganic & medicinal chemistry letters.

Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-

J. Wood, A. Poulsen, Meredith Williams, 2012, Journal of medicinal chemistry.

Association of IFN-γ : IL-10 Cytokine Ratio with Nonsegmental Vitiligo Pathogenesis

P. Jahan, M. K. Pasha, P. L. Komaravalli, 2015, Autoimmune diseases.

Effect of 1-aminobenzotriazole on the in vitro metabolism and single-dose pharmacokinetics of chlorzoxazone, a selective CYP2E1 substrate in Wistar rats

R. Mullangi, M. K. Pasha, N. R. Srinivas, 2005, Xenobiotica; the fate of foreign compounds in biological systems.

The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML

J. Wood, K. Goh, K. Ethirajulu, 2012, Blood Cancer Journal.

Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lympho

Anders Poulsen, Stéphanie Blanchard, Harish Nagaraj, 2011, Journal of medicinal chemistry.

Implication of podocin promoter variant haplotype in south Indian diabetic kidney patients

S. Raju, P. Jahan, M. K. Pasha, 2021 .

Expression Signatures of the Lipid-Based Akt Inhibitors Phosphatidylinositol Ether Lipid Analogues in NSCLC Cells

R. Greil, R. Weichselbaum, G. Prendergast, 2011, Molecular Cancer Therapeutics.

Supporting Information: Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl- ethoxy)-14,19-dioxa-5,7,26-triaza- tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment o

Harish, J. Wood, Meredith Williams, 2011 .